Theralase Technologies Inc Stock Price, News & Analysis

Theralase Technologies (TLTFF) has completed a non-brokered private placement, raising CAD 571,000 by issuing 2,855,000 units at CAD 0.20 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at CAD 0.30 per share for 5 years. The proceeds will support the company's ongoing Phase II Non-Muscle Invasive Bladder Cancer clinical study, Rutherrin development, and working capital needs. The company paid 30,000 broker shares and issued 15,000 broker warrants. Notably, insiders participated in the offering, purchasing 669,700 units for CAD 133,940. All securities issued are subject to a four-month hold period expiring October 11th, 2025.

Theralase Technologies (TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for cancer, bacteria and virus treatment, successfully completed its Annual General and Special Meeting on June 11th, 2025. The company hosted a virtual corporate presentation following the AGSM to outline its strategic objectives and upcoming milestones for 2025-2026. The presentation focused on current and planned clinical development programs aimed at accelerating the commercialization of Theralase's therapeutic technologies. The company emphasized its commitment to developing safe and effective therapeutics for destroying cancers, bacteria and viruses while minimizing impact on healthy tissue.

Theralase Technologies (TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, announces its Annual General and Special Meeting (AGSM) scheduled for June 11th, 2025 at 4:30 pm ET. The meeting will be held at the company's Toronto headquarters. Following the formal meeting, at 5:15 pm ET, the company will host a virtual presentation detailing its strategic objectives for 2025 and 2026, followed by a Q&A session concluding at 6:30 pm ET. Shareholders can join via Zoom or conference call, with an archived version available on the company's website the following business day.

Theralase Technologies reported its Q1 2025 financial results, showing total revenue of $91,190, a 48% decrease from Q1 2024. The company's Phase II Bladder Cancer Study has treated 82 patients (91% of target), with 62% showing Complete Response to the treatment. Key interim results show 42% of CR patients maintained response for 12+ months, with 100% experiencing no serious adverse events. The company completed two private placements raising $729,325 total. Theralase plans to complete Study II enrollment by summer 2025, targeting NDA submission in Q4 2026. The company is advancing Rutherrin for multiple cancer indications, planning Phase 0/I/II studies in Q1 2026 for GBM, NSCLC, pancreatic, colorectal, and muscle invasive bladder cancers.

Theralase Technologies (TLTFF) announced it will present new preclinical research on radiation-activated Rutherrin® at the ASTRO 2025 67th Annual Meeting in San Francisco. The study evaluates Rutherrin®, a ruthenium-based drug formulated with human transferrin, against radiation alone in treating cancer.

The research explores Rutherrin's dual cancer-fighting mechanism: immediate cytotoxicity through Reactive Oxygen Species generation and sustained immune response through Immunogenic Cell Death. Key aspects to be presented include tumor targeting, blood-brain barrier penetration, survival rates, and resistance inhibition.

The company plans to complete GLP toxicology studies in 2025 and aims to launch clinical studies in early 2026 targeting multiple cancers including GBM, lung, pancreatic, lymphoma, and colorectal cancers.

Theralase Technologies (TLTFF) has announced groundbreaking preclinical results showing that their radiation-activated Rutherrin® treatment is 100 times more effective at destroying cancer cells compared to radiation therapy alone. The company will present these findings at the ASTRO 2025 conference in San Francisco.

Key findings demonstrate that Rutherrin®, a ruthenium-based small molecule drug, shows selective tumor targeting, enhanced blood-brain barrier penetration with 10x higher concentrations in GBM tumors, and combines direct tumor cell destruction with immune activation. The treatment works through Radio Dynamic Therapy (RDT), generating Reactive Oxygen Species for immediate cytotoxicity and Immunogenic Cell Death for durable immune response.

The company plans to complete GLP toxicology studies in 2025 and launch clinical studies in early 2026, targeting GBM, lung, pancreatic, lymphoma, and colorectal cancers.

Theralase Technologies (TLTFF) provided a comprehensive corporate update on their clinical developments. The company has achieved 91% enrollment (82 out of 90 patients) in their Study II for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Interim results show a 62.3% Complete Response rate with 41.9% maintaining response at 15 months. The company plans to submit New Drug Applications to Health Canada and FDA in Q4 2026. Additionally, Theralase is advancing research in multiple areas including Glioblastoma Multiforme, Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, blood cancers, and HSV-1 treatment, with Phase I/II studies planned for 2026. The company has raised CAD 6.3 million over the last 2 years and is exploring US listing opportunities.

Theralase Technologies (TLTFF) presented interim clinical data from its Phase II BCG-Unresponsive NMIBC CIS study at major urological conferences. The data shows 62.5% of patients achieved Complete Response (CR), with 45% maintaining CR for at least 12 months. Notably, 20% of CR patients maintained response at 36 months, with one patient showing CR for over 7 years. The study enrolled 79 patients, with 100% reporting no serious adverse events related to the treatment. The company's RuvidarTM technology, activated by the TLC-3200 medical laser system, demonstrates promising results in destroying cancer cells through reactive oxygen species and immune system stimulation. Theralase plans to complete enrollment by mid-2025 and submit for Health Canada and FDA regulatory approval in late 2026.

Theralase Technologies (TLTFF) has announced a significant breakthrough in cancer treatment research. Their lead drug Ruvidar has been proven preclinically to effectively inhibit DeUbiquitinating Enzymes (DUBs), which are linked to various cancers and neurodegenerative diseases.

The research demonstrates that Ruvidar works through a dual mechanism: it inhibits DUBs activity in a dose-dependent manner and induces oxidative stress through Reactive Oxygen Species (ROS) production. At 100 μM concentration, Ruvidar nearly eliminates DUBs activity completely.

This discovery is particularly significant as DUBs are associated with drug resistance in cancer treatments. By targeting DUBs, Ruvidar could potentially be used in combination with various chemotherapy drugs and radiotherapy to combat chemoradiotherapy-resistant cancers.